NAC supplement for blood recovery after chemo in acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether taking N-acetylcysteine (NAC), an antioxidant supplement, after induction chemotherapy helps your blood cells recover faster and more completely. It is designed for adults with newly diagnosed low- or intermediate-risk acute myeloid leukemia (AML) who have achieved remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with acute myeloid leukemia (AML), not the M3 subtype.
- Your leukemia is classified as low-risk or intermediate-risk according to the 2022 European Leukemia Net (ELN) genetic guidelines.
- You are between 18 and 65 years old.
- You received induction chemotherapy with the HAA regimen (a combination of drugs). If you have a certain gene change (FLT3-ITD), you may have also received sorafenib.
- You do not have severe organ problems, uncontrolled infections, or conditions like heart failure, severe asthma, or liver/kidney issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
This study tests whether adding natural killer (NK) cell infusions to standard consolidation chemotherapy helps keep acute myeloid leukemia (AML) in remission. It's for people with AML who are already in remission after their first treatment.
This Phase 1/2 study tests what dose of N-acetylcysteine (NAC) is safe and potentially helpful for people with essential thrombocythemia, polycythemia vera, or myelofibrosis. It focuses on people who still have symptoms and meet blood and health requirements so researchers can monitor side effects and symptom changes.
This trial tests a new treatment called NCR300 to see if it can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It may help people who are at high risk of relapse.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
Hear when a new Acute Myeloid Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.